Trial · NCT07074561
The Synergism and Attenuation Effects of Electroacupuncture in the Treatment of Trigeminal Neuralgia
NCT07074561, Not applicable, Not yet recruiting, Yuanyuan Wu
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Synergism and Attenuation Effects of Electroacupuncture in the Treatment of Trigeminal Neuralgia. Trials, record NCT07074561. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07074561
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Synergism and Attenuation Effects of Electroacupuncture in the Treatment of Trigeminal Neuralgia
- NCT number
- NCT07074561
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 28 participants, estimated
- Lead sponsor
- Yuanyuan Wu
- Conditions
- Trigeminal Neuralgia
- Interventions
- CBZ placebo, CBZ, Electroacupuncture, Sham electroacupuncture
- First posted
- 2025-07-20
- Last updated
- 2025-07-20
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in Visual Analog Scale (VAS) scores from baseline to the end of the 4th week of treatment | Baseline, 4 weeks after treatment. | The Visual Analog Scale (VAS) consists of a 10-cm line, where '0' indicates 'no pain' and '10' represents 'unbearable pain,' with increasing pain intensity from 0 to 10. Patients self-assess their pain level by marking the scale, and the investigator records the score." |
| Secondary | Changes in Visual Analog Scale (VAS) scores | Baseline, 2 weeks after treatment, at 4-week follow-up. | Visual Analog Scale (VAS) consists of a 10-cm line, where '0' indicates 'no pain' and '10' represents 'unbearable pain,' with increasing pain intensity from 0 to 10. Patients self-assess their pain level by marking the scale, and the investigator records the score. VAS scores were assessed at baseline, the end of the 2nd week of treatment, and the end of the 4th week post-treatment (follow-up), to observe changes from baseline at the 2nd week of treatment and the 4th week post-treatment respectively. |
| Secondary | Pain Diary Card | Daily from enrollment through four weeks after treatment completion | Daily records of carbamazepine (CBZ)/CBZ-placebo medication adherence, pain episode frequency, and adverse reactions in both groups will be maintained until the end of follow-up. The recorded data will be used for intergroup comparisons and intra-group comparisons to evaluate the degree of pain status changes between groups and within individuals. |
| Secondary | Carbamazepine Adverse Reactions | Daily from enrollment through four weeks after treatment completion | |
| Secondary | Hepatorenal function | Baseline, 4 weeks after treatment. | This study will assess the degree of hepatocyte injury and glomerular filtration function. Additionally, the incidence of severe liver or kidney impairment will be evaluated. |
| Secondary | Changes in the The Self-Rating Anxiety Scale (SAS) | Baseline, 2 weeks after treatment, 4 weeks after treatment, at 4-week follow-up. | After completing each scale, the raw total score (X) is obtained by summing all item scores. This raw score is then multiplied by 1.25, to derive the standardized score (Y). The SAS cut-off value for clinical significance is a standardized score of 50, with severity classifications as follows: 50-59 indicates mild anxiety, 60-69 moderate anxiety, and scores above 69 severe anxiety. |
| Secondary | Changes in the Self-Rating Depression Scale (SDS) | Baseline, 2 weeks after treatment, 4 weeks after treatment, at 4-week follow-up. | The raw scores from each subscale are summed to obtain the total raw score, which is then multiplied by 1.25 to calculate the standard score. For the SDS, the cutoff for depression is a standard score of 53, with scores of 53-62 indicating mild depression, 63-72 indicating moderate depression, and scores above 72 indicating severe depression. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07074561
GET https://conductscience.org/api/trials/v1/NCT07074561/registered